Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):915–919. doi: 10.1054/bjoc.2000.1690

Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients

Y Suefuji 1, T Sasatomi 2, S Shichijo 3, S Nakagawa 2, H Deguchi 2, T Koga 2, T Kameyama 1, K Itoh 3
PMCID: PMC2363830  PMID: 11286471

Abstract

We recently reported the SART3 tumour-rejection antigen as possessing tumour epitopes capable of inducing HLA-class I-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in breast cancer to explore an appropriate molecule for use in specific immunotherapy of breast cancer patients. The SART3 antigen was detected in all of the breast cancer cell lines tested, 30 of 40 (75%) breast cancer tissue samples, and 0 of 3 non-tumourous breast tissue samples. SART3 derived peptides at positions 109–118 and 315–323 induced HLA-A24 restricted CTLs that reacted to breast cancer cells from the peripheral blood mononuclear cells (PBMCs) of breast cancer patients. Therefore, the SART3 antigen and its peptides could be an appropriate molecule for use in specific immunotherapy of the majority of HLA-A24-positive breast cancer patients. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: SART3 antigen, breast cancer, HLA-A24, immunotherapy, cancer vaccine

Full Text

The Full Text of this article is available as a PDF (76.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apostolopoulos V., Karanikas V., Haurum J. S., McKenzie I. F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol. 1997 Dec 1;159(11):5211–5218. [PubMed] [Google Scholar]
  2. Farace F., Angevin E., Dietrich P. Y., Leboullaire C., Vanderplancke J., Escudier B., Triebel F. Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer. 1995 Sep 4;62(5):523–528. doi: 10.1002/ijc.2910620506. [DOI] [PubMed] [Google Scholar]
  3. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J. J., De Plaen E., Lethé B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1;179(3):921–930. doi: 10.1084/jem.179.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P. F., Sette A., Appella E., Rosenberg S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15;154(8):3961–3968. [PubMed] [Google Scholar]
  5. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P. F., Rivoltini L., Yannelli J. R., Appella E., Rosenberg S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1;180(1):347–352. doi: 10.1084/jem.180.1.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kawamoto M., Shichijo S., Imai Y., Imaizumi T., Koga T., Yanaga H., Itoh K. Expression of the SART-1 tumor rejection antigen in breast cancer. Int J Cancer. 1999 Jan 5;80(1):64–67. doi: 10.1002/(sici)1097-0215(19990105)80:1<64::aid-ijc13>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  7. Kikuchi M., Nakao M., Inoue Y., Matsunaga K., Shichijo S., Yamana H., Itoh K. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer. 1999 May 5;81(3):459–466. doi: 10.1002/(sici)1097-0215(19990505)81:3<459::aid-ijc21>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  8. Linehan D. C., Goedegebuure P. S., Peoples G. E., Rogers S. O., Eberlein T. J. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol. 1995 Nov 1;155(9):4486–4491. [PubMed] [Google Scholar]
  9. Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M. H., Rankin E., Parmiani G., Arienti F., Humblet Y. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999 Jan 18;80(2):219–230. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  10. Murayama K., Kobayashi T., Imaizumi T., Matsunaga K., Kuramoto T., Shigemori M., Shichijo S., Itoh K. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother. 2000 Sep-Oct;23(5):511–518. doi: 10.1097/00002371-200009000-00001. [DOI] [PubMed] [Google Scholar]
  11. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998 Mar;4(3):328–332. doi: 10.1038/nm0398-328. [DOI] [PubMed] [Google Scholar]
  12. Robbins P. F., El-Gamil M., Li Y. F., Fitzgerald E. B., Kawakami Y., Rosenberg S. A. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 1997 Jul 1;159(1):303–308. [PubMed] [Google Scholar]
  13. Robbins P. F., El-Gamil M., Li Y. F., Kawakami Y., Loftus D., Appella E., Rosenberg S. A. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996 Mar 1;183(3):1185–1192. doi: 10.1084/jem.183.3.1185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dudley M. E., Schwarz S. L., Spiess P. J. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321–327. doi: 10.1038/nm0398-321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Russo V., Traversari C., Verrecchia A., Mottolese M., Natali P. G., Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer. 1995 Jun 22;64(3):216–221. doi: 10.1002/ijc.2910640313. [DOI] [PubMed] [Google Scholar]
  16. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  17. Traversari C., Meazza R., Coppolecchia M., Basso S., Verrecchia A., van der Bruggen P., Ardizzoni A., Gaggero A., Ferrini S. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther. 1997 Oct;4(10):1029–1035. doi: 10.1038/sj.gt.3300489. [DOI] [PubMed] [Google Scholar]
  18. Yamauchi H., O'Neill A., Gelman R., Carney W., Tenney D. Y., Hösch S., Hayes D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997 Jul;15(7):2518–2525. doi: 10.1200/JCO.1997.15.7.2518. [DOI] [PubMed] [Google Scholar]
  19. Yang D., Nakao M., Shichijo S., Sasatomi T., Takasu H., Matsumoto H., Mori K., Hayashi A., Yamana H., Shirouzu K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 1999 Aug 15;59(16):4056–4063. [PubMed] [Google Scholar]
  20. Zaks T. Z., Rosenberg S. A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998 Nov 1;58(21):4902–4908. [PubMed] [Google Scholar]
  21. van der Bruggen P., Bastin J., Gajewski T., Coulie P. G., Boël P., De Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec;24(12):3038–3043. doi: 10.1002/eji.1830241218. [DOI] [PubMed] [Google Scholar]
  22. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES